Hansa Biopharma AB

Equities

HNSA

SE0002148817

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 07:59:48 2024-03-28 am EDT 5-day change 1st Jan Change
29.1 SEK -0.89% Intraday chart for Hansa Biopharma AB +0.34% +11.07%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hansa Biopharma Hires New CFO MT
Hansa Biopharma AB Announces CFO Changes CI
Transcript : Hansa Biopharma AB, Q4 2023 Earnings Call, Feb 02, 2024
Hansa Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Hansa Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hansa Biopharma and Newbridge Pharmaceuticals Forms Partnership to Enable Supply of Novel Treatment Idefirix to Kidney Transplant Patients in the Middle East and North Africa CI
Hansa Biopharma AB Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 CI
Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation CI
Hansa Biopharma Nomination Committee Formed CI
Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial CI
Hansa Biopharma Expects Up to SEK85 Million Annual Savings from Workforce Reduction Plan MT
Hansa Biopharma Plans Restructuring to Strengthen Long-Term Competitiveness and Advance Key Deliverables CI
Sweden's Hansa Biopharma CFO to Depart in February 2024 MT
Hahansa Biopharma AB Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024 CI
Transcript : Hansa Biopharma AB, Nine Months 2023 Earnings Call, Oct 26, 2023
Hansa Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Hansa Biopharma's Follow-up Study Shows High Survival Rate for Imlifidase-enabled Kidney Transplant Patients MT
Hansa Biopharma Announces Results from an Extended Pooled Analysis Using Data from the 17-Hmedides-14 Study, an International Long-Term Follow-Up Study of Patients Who Have Received A Kidney Transplant Following Desensitization with Imlifidase, Showing Sustained Positive Outcomes Out to 5 Years in the Majority of Highly Sensitized Patients Who Received an Imlifidase-Enabled Kidney Transplant CI
Hansa Biopharma to Finalize Randomization in Late-stage Kidney Study by Mid-2024 MT
Hansa Biopharma Provides Clinical Pipeline Update on Confides Trial CI
Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients CI
Hansa Biopharma’s Lead Enzyme Candidate Shows Safety, Tolerability in First Human Trial MT
Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487 CI
Sweden’s Hansa Biopharma Appoints New Chief Scientific Officer MT
Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma, Effective 1 December 2023 CI
Chart Hansa Biopharma AB
More charts
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company's operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS's goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company's patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
29.1 SEK
Average target price
112.5 SEK
Spread / Average Target
+286.60%
Consensus
  1. Stock
  2. Equities
  3. Stock Hansa Biopharma AB - Nasdaq Stockholm
  4. News Hansa Biopharma AB
  5. Hansa Biopharma Starts Phase 3 For Autoimmune Drug Imlifidase; Shares Up 7%